Quick Answer
Caris Life Sciences, Inc. reported Long-Term Debt of $378.82 million for fiscal year 2025.
Caris Life Sciences, Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2025 | $378.82M | +18.6% |
| 2024 | $319.44M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $376.30M | — | +0.7% |
| June 30, 2025 | $373.61M | — | +17.0% |
| December 31, 2024 | $319.44M | — | — |
- Caris Life Sciences, Inc. showed an increase of +18.6% in Long-Term Debt compared to the prior fiscal year.
- Over the 2024–2025 period, Caris Life Sciences, Inc.’s long-term debt has grown by 18.6% (from $319.44 million to $378.82 million).
- The most recent figure is from Caris Life Sciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: